Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
Lung Cancer: Targets and Therapy · 2020-09 · Volume 11 · 59-71
DOI: 10.2147/lctt.s262822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung Cancer: Targets and Therapy, 2020-09. Verfasst von Wang Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021, People's Republic of China.
Zitieren
APA
Yang, W., Chen, N., Li, L., Chen, X., Liu, X., Zhang, Y., & Cui, J. (2020). Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations. Lung Cancer: Targets and Therapy, Volume 11, 59-71. https://doi.org/10.2147/lctt.s262822
Vancouver
Yang W, Chen N, Li L, Chen X, Liu X, Zhang Y, et al. Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations. Lung Cancer: Targets and Therapy. 2020;Volume 11:59-71. doi:10.2147/lctt.s262822
BibTeX
@article{Yang2020,
author = {Yang, Wang and Chen, Naifei and Li, Lingyu and Chen, Xiao and Liu, Xiangliang and Zhang, Yongfei and Cui, Jiuwei},
title = {Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations},
journal = {Lung Cancer: Targets and Therapy},
year = {2020},
volume = {Volume 11},
pages = {59--71},
doi = {10.2147/lctt.s262822}
}
EUVIMED